Drug Information

Drug General Information
Drug ID
D0T8MA
Former ID
DIB005567
Drug Name
ATN-224
Synonyms
Angiogenesis inhibitor, Attenuon; Superoxide dismutase 1 inhibitor, Attenuon
Drug Type
Small molecular drug
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 2 [521926]
Company
University of Michigan
Formula
C10H30MoN2O2S4
Canonical SMILES
S=[Mo-2](=S)(=S)=S.C[N+](C)(CCO)C.C[N+](C)(CCO)C
CAS Number
CAS 649749-10-0
PubChem Compound ID
18442052
Target and Pathway
Target(s) Superoxide dismutase [Cu-Zn] Target Info Inhibitor [528378]
BioCyc Pathway Reactive oxygen species degradation
KEGG Pathway Peroxisome
Amyotrophic lateral sclerosis (ALS)
Huntington's disease
Prion diseases
NetPath Pathway TCR Signaling Pathway
Pathway Interaction Database Validated nuclear estrogen receptor alpha network
FOXA1 transcription factor network
PathWhiz Pathway Degradation of Superoxides
Reactome Platelet degranulation
Detoxification of Reactive Oxygen Species
WikiPathways Oxidative Stress
Copper homeostasis
Detoxification of Reactive Oxygen Species
Nifedipine Activity
Amyotrophic lateral sclerosis (ALS)
Dopamine metabolism
AGE/RAGE pathway
Folate Metabolism
Vitamin B12 Metabolism
Selenium Micronutrient Network
References
Ref 521926ClinicalTrials.gov (NCT00405574) Study of ATN-224 in Patients With Prostate Cancer. U.S. National Institutes of Health.
Ref 528378Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.